Suzhou New District issues a business license to the biotechnology branch of Fujifilm Irvine Scientific on Dec 1. [Photo/WeChat account: snd-szgxqfb]
The biotechnology branch of Fujifilm Irvine Scientific, a global life sciences and medical media provider with an array of innovative products, was issued a business license from the Suzhou New District government on Dec 1.
The company was one of the most important investments of Fujifilm Irvine Scientific in China this year. It will take advantage of its parent company's world-leading cell culture technology, while mainly engaging in the production, as well as research and development of vaccines and other upstream media for biological medicines.
A Fujifilm Irvine Innovation Cooperation Center was launched on the same day, which has gained an initial investment of 19.5 million yuan ($3.06 million).
Kenichi Tanaka, CEO of Fujifilm China, said that the project was an important part of Fujifilm's life sciences business.
"With our strong research and development capabilities and quality control capabilities, we will be committed to developing and providing tailored media that best suit our customers' needs," Tanaka said.
"In the future, we will combine Fujifilm's own advantages to help China improve its remote medical treatment, medical grading, as well as the quality and efficiency of medical care. We are looking forward to the new Suzhou company and the innovation cooperation center bringing out its scientific capabilities to help China biological medicine enterprise develop better."
Song Changbao, acting chief of SND, said the district will continue to support Fujifilm and he hoped the company will be put into operation as soon as possible.
